XYLASED 100 mg/ml injection solution
Injectable solution containing xylazine for sedation, myorelaxation and analgesia of horses and cattle.
|type of preparative:||Analeptic, anaesthetic, hypnotics|
|target species animals:||Horse, Cattle|
Statement of active and other substances
1 ml of the injection solution contains:
Xylazinum (ut xylazini hydrochloridum) 100.0 mg
Injection solution. Clear colourless solution with no visible particles.
Indication for use specifying the target animal species
Sedation, myorelaxation and analgesia during minor surgical procedures.
Sedation and myorelaxation.
Posology and method of administration
Method of administration:
Single slow intravenous or intramuscular administration.
When administered intramuscularly, the product may be applied using injection or narcotizing shot.
Recommended doses for individual routes of administration:
- intravenous administration: 0.03–0.1 ml of product/100 kg body weight, which is equivalent to the xylazine dose of 0.03–0.1 mg/kg body weight.
- intramuscular administration: 0.05–0.3 ml of product/100 kg body weight, which is equivalent to the xylazine dose of 0.05–0.3 mg/kg body weight.
Method of administration:
Single slow intravenous administration.
Recommended dose: 0.6–1 ml of product/100 kg body weight, which is equivalent to the xylazine dose of 0.6–1 mg/kg body weight.
The stopper can be punctured up to 50 times.
Do not administer to the animals with cardiovascular insufficiencies and disorders.
Do not administer to the animals with the signs of arterial hypotension and to the animals in the state of shock.
Do not administer to the animals with renal insufficiency and obturation of the urinary tract.
Do not administer to the animals with hepatic insufficiency.
Do not administer to the animals with respiratory insufficiency.
Do not administer to the debilitated and dehydrated animals.
Do not administer to the animals with diabetes mellitus.
Do not administer to the animals with rumen dysfunction, disorder of gastrointestinal motility and with metabolic acidosis.
Do not administer to the animals with laminitis in vasoconstrictive phase.
Bradycardia, hypotension. Bradypnoea to respiratory arrest.
Reversible local irritation when administered intramuscularly.
Increased salivation, inhibited motility of forestomachs, tympanites, inability to move the tongue, regurgitation.
Uterus contractions. Paradox excitation (at higher doses).
Hyperglycaemia. Polyuria with glycosuria. Transient inhibition of the regulation of the body temperature.
Reversible changes in the blood count (erythropaenia, lower haematocrit, leukopaenia with lymphopaenia and neutrophilia).
Alteration of biochemical parameters in plasma (mild decrease in total protein, higher concentration of urea).
Bradycardia, reversible arrhythmia and hypotension. Bradypnoea to respiratory arrest.
Paradox excitation (at higher doses). Hyperglycaemia.
Polyuria without glycosuria. Reversible changes in the blood count (lower haematocrit).
Meat: 3 days. Milk: 36 hours.
Do not use in horses the meat of which is intended for human consumption. Do not use in horses producing milk which is intended for human consumption.
Special precautions for storage
Do not freeze. Keep the vial in the box, protected from light.
Special warnings for each target species
The heads and necks of lying ruminants should be positioned low in order to prevent aspiration of food and saliva.
To minimize the risk of regurgitation, the animals should be fasting for 24 hours prior to administration and appropriately limited in water.
Special precautions for use in animals
The animals sedated using xylazine should be handled carefully. They can be awakened by external stimuli and they can make sudden targeted protective movements. When handling horses, be aware of the hazard of protective movements of the animal's rear legs. At intravasal administration, intravenous administration is preferred. Intraarterial administration may lead to a collapse.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Avoid accidental self-administration of injection or narcotizing shot. Protect the needle till the moment of product administration. In case of accidental ingestion or self-injection, seek medical advice immediately and show the package leaflet or the label to the general practitioner. DO NOT DRIVE A CAR as you may be sedated and your blood pressure may be changed.
Avoid direct contact with skin, eyes and mucous membranes. After contact with skin, wash the affected skin immediately with plenty of clean water. Remove contaminated clothing which is in direct contact with skin.
In case of accidental contact with eyes, rinse the eyes immediately with plenty of water. If symptoms have developed, seek medical advice.
In case a pregnant woman is handling the product, increased caution is necessary to prevent self-injection. Uterine contraction and decrease in the blood pressure of the foetus may occur after accidental systemic exposure.
Do not smoke, drink or eat while handling the product.
To the physician:
Xylazine is the alpha2-adrenoceptor agonist. Following absorption, the clinical signs may include dose-dependent sedation, respiratory depression, bradycardia, hypotension, dry mouth and hyperglycaemia. Cases of ventricular arrhythmia have also been reported. Respiratory and haemodynamic signs should be treated symptomatically.
Shelf life inside an intact package: 2 years.
Shelf life after first opening the immediate packaging: 28 days.
1 x 10 ml, 1 x 50 ml
+420 517 318 598